Tuesday, 19 August 2003: 09:00-10:30
Ontario Room (Sheraton Hotel and Towers)

S030 New Findings in the Pharmacology of Dementia

 S030-005 A 26 Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Divalproex Sodium ER augmentation of Donepezil for Cognition, Hippocampal Volume, and Behavior in Mild/Moderate Alzheimer's Disease (AD)
Peter Aupperle, Steven Sohnle, David Foran, Kevin DeMarco, Matthew Bohm, Julie Coleman, Ben Palombo
 S030-006 Donepezil is Safe and Well Tolerated in Patients with Vascular Dementia
Ben Seltzer, Raymond D Pratt, Carlos A Perdomo
 S030-007 Donepezil Shows Significant Benefits in Global Function, Cognition, ADL and Behavior in Patients with Severe Alzheimer’s Disease
S Gauthier, H Feldman, J Hecker, B Vellas, Y Xu, J Ieni, E Schwam
 S030-001 Donepezil-Treated Patients Demonstrate Cognitive Benefits: A Comparison of Alzheimer’s Disease Versus Vascular Dementia
Alistair Burns, Raymond D Pratt, Carlos A Perdomo
 S030-002 Galantamine Demonstrates Sustained Safety and Efficacy over 24 Months in Patients with Probable Vascular Dementia
Serge Gauthier, H. Robert Brashear, Sean Lilienfeld
 S030-003 Risperidone Versus Melperone - Superior Effects of Risperidone on a Broad Spectrum of BPSD and other Symptoms in Dementia
Martin Haupt, Steffen Heger, Klaus Rettig, Hildegard Delius-Stute, Susanne Schwalen, Andreas Schreiner
 S030-004 The Effects of Cholinergic Therapy (Donepezil) in Alzheimer’s Disease as Demonstrated by Imaging the Post-Synaptic Muscarinic Receptor
Clive Holmes, Paul M Kemp, Sandra Hoffmann, Suzanne Wilkinson, Maureen Zivanovic, James Thom, Livia Bolt, John Fleming, David Wilkinson

Back to The Eleventh International Congress